CD40/TNFRSF5 Antibody (G28-5)

This product is manufactured by Eurobio Scientific (formerly Dendritics) and distributed by Novus Biologicals.

CD40 and its ligand CD154 are members of the tumor necrosis factor receptor (TNFR) and TNF families, respectively, that play key roles in signaling pathways mediating cell growth, survival and differentiation in B-lymphocytes (reviewed in Quezada et al 2004). The CD40 receptor is a 45-50 kDa glycoprotein and is expressed on the surface of B-lymphocytes, some activated T-cells, monocytes, follicular dendritic cells, basal epithelial cells, and in some epithelial and non-epithelial carcinomas. The functions of CD40 have been most extensively studied in B-cells. Ligation of B CD40 by CD154, expressed on activated T cells, stimulates B cell proliferation, differentiation, isotype switching, upregulation of surface molecules contributing to antigen presentation, development of the germinal center, and the humoral memory response. Several distinct structural motifs in the CD40 cytoplasmic domain regaulate various CD40 signaling pathways. A major CD40 signaling pathway activated from CD154 ligand binding is the canonical pathway to the transcription factor family NF-kB, a family of genes mediating immune and inflammatory responses. Although CD40 has been extensively studied as a plasma membrane-associated growth factor membrane receptor. it has also been identified in the cytoplasm and nucleus of normal and neoplastic B-lymphoid cells (Lin-Lee et al. 2006). Other growth factor receptors, including EGF, FGF, and TGF-B have also been identified in the nuclus. It is thought that plasma membrane receptor signaling may be followed by nuclear migration of signaling pathway components. The presence of CD40 in the nucleus of activated normal B lymphocytes and neoplastic B-lymphoid cells suggests that CD40 may play a more complex role in regulating essential growth and survival pathways in B-lymphocytes than previously thought.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Showing Publications 1 - 9 of 9.

Publications using DDX0130P-100	Applications	Species
Wu HH, Ralph KL, Sepuldeva E Et al. An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases International journal of pharmaceutics 2021-10-06 [PMID: 34624444]
Clark EA. A Short History of the B-Cell-Associated Surface Molecule CD40. Front Immunol 2014-09-01 [PMID: 25324844]
Clark EA et al. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. 1986. 83: 4494-4498. J Immunol. 2012-05-01 [PMID: 22517865]
Bishop GA. The power of monoclonal antibodies as agents of discovery: CD40 Revealed as a B lymphocyte costimulator. J Immunol 2012-05-01 [PMID: 22517864]
Lefevre EA et al. Fibrinogen is localized on dark zone follicular dendritic cells in vivo and enhances the proliferation and survival of a centroblastic cell line in vitro. J Leukoc Biol 2007-09-01 [PMID: 17550975]
Dahlenborg K et al. Signals sustaining human immunoglobulin V gene hypermutation in isolated germinal centre B cells. Immunology 2000-10-01 [PMID: 11012774]
Altenburg A et al. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol 1999-04-01 [PMID: 10201939]
de Saint Vis B et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998-09-01 [PMID: 9768752]
Clark EA et al. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A 1986-06-01 [PMID: 3487090]

Array DDX0130P-100

• CD40/TNFRSF5 Antibodies
• CD40/TNFRSF5 Antibody Pair
• CD40/TNFRSF5 ELISA Kit
• CD40/TNFRSF5 Lysate
• CD40/TNFRSF5 Proteins
• CD40/TNFRSF5 Proteins and Enzymes
• CD40/TNFRSF5 ELISAs